Newsroom | 4136 results

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. “Our team continues to be very disciplined about executing our plans and is making strong progress advancing our clinical stage PBGENE-HBV program whil...

MINNEAPOLIS--(BUSINESS WIRE)--NMDPSM, a global nonprofit leader in cell therapy, and its collaborative research program, CIBMTR® (Center for International Blood and Marrow Transplant Research®), announced today that the first patient began treatment as part of the groundbreaking ACCELERATE clinical trial, which compares novel GVHD prevention strategies against the current, standard of care regimen of post-transplant cyclophosphamide (PTCy) for patients undergoing mismatched unrelated donor (MMU...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, announced ELIMINATE-B results as of the data cutoff of July 28, 2025. Data include completed Cohort 1 (dosed at 0.2 mg/kg), the lowest dose level of the ELIMINATE-B trial, and initial safety data from Cohort 2 (dosed at 0.4 mg/kg). The ELIMINATE-B trial is designed...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its second quarter 2025 financial and operating results on Tuesday, August 12, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, August 12, 2025, at 4:30 p.m. Eastern T...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving lif...

シアトル＆ドイツ・ハイデルベルク--(BUSINESS WIRE)--（ビジネスワイヤ） -- 医薬品製造受託機関（CDMO）のAGCバイオロジクスは、特殊ワクチンメーカーであるバルネバ（Nasdaq：VALN、Euronext Paris：VLA）と開発・製造サービス契約を締結し、CDMOのハイデルベルク拠点において、治験が進行中の四価赤痢菌バイオコンジュゲートワクチンの原薬を供給することを発表しました。 バルネバは、リマテック・バイオロジクスからワクチン候補の独占ライセンスを取得しており、リマテック・バイオロジクスはこれまで、AGCバイオロジクスと提携し、ヒト初回投与試験用のワクチンの複合タンパク質多糖複合体のGMP準拠製造および品質管理体制を確立してきました。バルネバとの新たな提携の目的は、AGCバイオロジクスのハイデルベルク拠点が持つ、複合分子を臨床段階へと導くノウハウを活用し、第II相供給体制を確立することにあります。バルネバとリマテックは、4月に乳児を対象とした第II相試験、2024年11月に第IIb相ヒトチャレンジ試験（CHIM）を開始したことを発表しています。 細菌性...

SEATTLE & HEIDELBERG, Deutschland--(BUSINESS WIRE)--AGC Biologics, Ihr kompetenter CDMO-Experte, gab heute eine Vereinbarung über Entwicklungs- und Fertigungsdienstleistungen mit dem Spezialimpfstoffhersteller Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) bekannt, wonach AGC Biologics in seinem Werk in Heidelberg den Wirkstoff für einen vierwertigen Shigella-Biokonjugat-Impfstoff in der klinischen Entwicklung liefern wird. Valneva hat die exklusive Lizenz für den Impfstoffkandidaten von LimmaT...

SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP...

LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. (“AvenCell”), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership...